Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 9, 2022Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai“) announced today that, as part of the public comment period, its U.S. subsidiary, Eisai Inc., has submitted formal comments...
Jan 27, 2022Cambridge, Mass. – January 27, 2022– Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study,...
Jan 24, 2022Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the expansion of its leadership team to include Tricia Brooks as Vice President & Head of Office, Government...
Jan 20, 2022KENILWORTH, N.J., and NUTLEY, N.J., January 20, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the publication of results from the Phase 3...
-
Jan 18, 2022EISAI'S ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of...